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Abstract. The health-care needs and resources of disease-endemic regions such as west Africa have been a major
focus during the recent Ebola outbreak. On the basis of that experience, we call attention to two priorities that have
unfortunately been ignored thus far: 1) the development of clinical research facilities and 2) the training of host country
investigators to ensure that the facilities and expertise necessary to evaluate candidate interventions are available
on-site in endemic regions when and where they are needed. In their absence, as illustrated by the recent uncertainty
about the use of antivirals and other interventions for Ebola virus disease, the only treatment available may be
supportive care, case fatality rates may be unacceptably high and there may be long delays between the time potential
interventions become available and it becomes clear whether those interventions are safe or effective. On the basis of
our experience in Mali, we urge that the development of clinical research facilities and the training of host country
investigators be prioritized in disease-endemic regions such as west Africa.
BACKGROUND
As highlighted by the recent Ebola virus disease out-
break,1,2 impoverished regions with endemic disease such as
west Africa are at risk of morbidity, mortality, economic dis-
ruption, and civil strife from the epidemic spread of diseases
for which prevention and treatment are limited or nonexis-
tent.3 The major reasons for this disparity are 1) the diseases
that pose the greatest challenge are more frequent in regions
with insufficient resources to support drug and vaccine devel-
opment and few or no opportunities to profit from those
investments4–6 and 2) the numbers of clinical research facili-
ties and trained personnel (clinical investigators, nurses, and
laboratory technologists) available to evaluate candidate inter-
ventions are severely limited.6
The premise underlying this article is that the development
of clinical research facilities and the training of host country
investigators in endemic regions will accelerate the evaluation
of interventions to reduce morbidity and mortality. If these
strategies are successful, which we expect they will be, they
will relieve a bottleneck in the progression from basic
research to implementation (bench to bedside) by decreasing
the time required to evaluate candidate interventions. These
strategies also have the potential to ensure that a single set of
standards for efficacy and safety testing is used across the
globe, that is, the standards used to evaluate drugs, vaccines,
and other candidate interventions are the same in impoverished
disease-endemic regions as in NorthAmerica, Europe, Australia,
and the developed countries of Asia.7,8
RATIONALE
Neither clinical research nor the training of host country
investigators to perform clinical research is currently a priority
in endemic regions. In addition, health facilities potentially
available for clinical research are typically overwhelmed by
large numbers of patients seeking care, a situation that is
often exacerbated by national health budgets providing less
than $20 per person per year for all preventive and curative
health services (Guinea, Liberia, Sierra Leone, and others).9
As a result, clinical research in disease-endemic regions often
begins with small pilot studies performed by investigators with
common interests in scientific questions linked to disease con-
trol with access to grant funds that can be used to perform the
initial pilot studies.
In this case, the initial discussions about clinical research
in Mali began in 2004–2006 because phase 1 (pharmacology,
safety) studies of a candidate antimalarial drug in healthy
subjects in the United States had shown that the compound
being studied (AQ-13) was active in vitro against known
drug-resistant Plasmodium falciparum and as safe as chloro-
quine in human subjects.10,11 Based on those discussions, the
Faculty of Medicine and Ministry of Health set aside funds
to build a clinical research center on the campus of their
major teaching hospital (the Hôpital Point G). The rationale
for that decision was to perform phase 2 (efficacy) studies of
the candidate antimalarial at the new clinical research center
as a test case to examine the feasibility and potential value
of clinical trials that required intensive inpatient studies at a
clinical research facility linked to a Faculty of Medicine
within the disease-endemic area.
EXISTING INFRASTRUCTURE
The development of a clinical research center and the train-
ing of host country investigators at the University of Bamako
occurred in an environment where African and western inves-
tigators had worked together for more than two decades,
beginning with studies of mosquito vectors led by Touré12 and
Gwadz.13 On the basis of those and other experiences (e.g., at
the Medical Research Council Unit in The Gambia), it is
reasonable to expect that the development of clinical research
facilities and the training of host country investigators in
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other regions will succeed most frequently at institutions
with an established tradition of international collaboration in
clinical research.
BUILDING AND ACTIVATING THE CLINICAL
RESEARCH CENTER
During the subsequent 5 years (2007–2012; Figure 1), the
clinical research center was designed and built on the cam-
pus of the Hôpital Point G (Figure 2, Supplemental Table 1)
despite delays due to price increases and other challenges.
This is because the commitment to develop a clinical research
center was shared by the Ministry of Health, the Division of
Clinical Research (DCR) at National Institute of Allergy and
Infectious Diseases (NIAID), and extramural investigators
and was based on its anticipated value for the entire west
African region. Subsequently (during 2012 and the first half
of 2013), furnishings provided by the DCR were installed,
including desks for physicians and nurses; a table and chairs
for a conference room; plumbing fixtures (sinks, toilets); and
physician’s office furniture (examination tables, overhead
lights, ophthalmoscopes, and otoscopes). The purposes of this
equipment were to facilitate follow-up visits, ophthalmologic
examinations, timed venipunctures and finger sticks, the place-
ment of electrodes for Holter recordings, and the computer-
based analysis of Holter recordings and other study data.
INITIAL INPATIENT STUDIES
After the training of host country investigators and staff
(Table 1), 33 subjects with uncomplicated P. falciparum
malaria (males ≥ 18 years of age) were enrolled in a phase 2
Food and Drug Administration (FDA)–approved efficacy
(proof of concept) study to compare an investigational
antimalarial (AQ-13) to the currently recommended first-
line treatment of uncomplicated P. falciparum malaria
(Coartem®, Novartis, Beijing, China for Novartis, Pharma
AG, Basel, Switzerland).14 After screening, subjects who
provided their informed consent were randomized to either
Coartem or the investigational antimalarial, admitted to the
clinical research center for 5–6 inpatient days (3 days of
treatment and observation plus 2–3 additional days of obser-
vation) before discharge on day 6–7, and followed twice
weekly as outpatients (weeks 2–6 [days 8–42]) for recurrent
parasitemia as evidence of treatment failure. This approach
was based in part on previous studies of severe malarial ane-
mia15 and has shown that intensive inpatient studies (4 days
of 24-hour Holter recordings, 25 timed blood samples on
days 1–6 and 24-hour urine collections on days 1–4) can be
performed in the disease-endemic area based on patient care
and clinical observation provided by host country investiga-
tors, pharmacists, and nurses.
EBOLATESTING
The need for rapid diagnostic testing during the 2014
Ebola outbreak16 provided an opportunity to use the existing
infrastructure in Mali (developed with support from the
DCR, the Division of Intramural Research at NIAID/
National Institutes of Health and the Centers for Disease
Control and Prevention) to provide more rapid diagnosis of
Ebola infection. For example, the enhanced biosafety level
(BSL) 3 facility developed as part of an International Center
of Excellence for Research in Mali was used to ensure that
Ebola clinical specimens were inactivated without inadver-
tent exposure of laboratory personnel. After inactivation
under enhanced BSL-3 biocontainment conditions,17 those
specimens were tested using a two-target reverse transcrip-
tase polymerase chain reaction specific for the polymerase
and surface glycoprotein genes of the Ebola virus in a con-
ventional BSL-2 laboratory.17–19 This strategy permitted the
diagnosis of Ebola within 3 hours after specimens were
received from the field. As a result, this facility in Bamako
FIGURE 1. Steps in the development of a clinical research center in Mali. After the initial design and architectural phase (2004–2006), con-
struction of the clinical research center took place from 2007 to 2012. After the installation of plumbing, electricity, and furniture in 2012–2013,
the center was occupied in early 2013 and the initial clinical studies of an investigational antimalarial began in July 2013.
FIGURE 2. Clinical research center in Mali. The new clinical
research center in Mali is on the campus of the major teaching hospi-
tal of the University of Bamako (Hôpital Point G). The decision to
develop a clinical research center in Mali was based on commitments
shared by the Ministry of Health, the Division of Clinical Research
(DCR) at National Institute of Allergy and Infectious Diseases
(NIAID) and extramural investigators and was based on the antici-
pated benefits of such a facility for the entire west African region.
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became a reference laboratory for affected areas in Mali,
because its results were accurate and it reduced the time
required to transport specimens to a diagnostic laboratory
from 3 days to 2–3 hours.
HOST COUNTRY BENEFITS
Direct benefits. The development of a clinical research
facility, the training of host country investigators, and the per-
formance of an FDA-approved phase 2 clinical trial described
here provide examples of strategies to address the need to
evaluate candidate interventions in endemic areas that
became clear during the Ebola outbreak.20,21 Please note that
there is reason to expect additional clinical trials of Ebola-
related interventions because a candidate vaccine has been
shown to be safe and immunogenic in humans,22 the post-
exposure treatment with candidate vaccines may prevent
infection and disease,23 and a recent study suggests that
immunization may reduce human-to-human transmission dur-
ing an outbreak.24 In the short term, the assistance provided
by western governments such as the United States, United
Kingdom, France, and others has been invaluable. However,
in the long-term, the need to evaluate candidate interventions
can truly be resolved only by the development of clinical
research facilities and laboratories staffed by host country
investigators on-site who are knowledgeable about the dis-
eases being studied and have been trained to perform clinical
research. Please note that this challenge (bottleneck) is likely
to persist for the foreseeable future because investigators in
industry and academia are now identifying candidate interven-
tions faster than they can be evaluated by the few clinical
research facilities available currently in endemic regions.21
Indirect benefits. The indirect benefits expected with this
strategy include 1) more rapid and more rigorous evaluation
of candidate interventions in endemic regions (reduction of
the bottleneck described above), 2) improved teaching and
patient care in disease-endemic areas provided by host coun-
try investigators who themselves are actively involved in clin-
ical research, consistent with the previous experience of
developed countries with clinical research centers, 3) better
health outcomes in endemic regions from the implementa-
tion of interventions found to be effective and the exclusion
of interventions found to be ineffective or harmful, and
4) the development of a health research career niche for
which the best-prepared individuals will be host country
investigators knowledgeable about the diseases being studied
who have been trained to perform clinical research.
CONCLUSIONS
On the basis of our experience in west Africa, we are con-
vinced that the development of clinical research facilities and
the training of host country investigators can improve health
outcomes and the quality of medical and public health
TABLE 1
Training of host country investigators and staff
2004–2006 (planning) 2007–2012* (training) 2013–2015 (phase 2 study)
Mali PI, senior investigators,
internal medicine physicians
Review of study protocol and
clinical research training in
the United States†
Review of study design and




Consultants in cardiology Review of the phase 1 studies




Screening plus follow-up for AEs
(especially, arrhythmias and
heart block)
Consultant in ophthalmology Review of phase 1 studies and
the phase 2 study design
Screening to identify volunteers
with normal ocular function§
Exam to detect ocular AEs based
on repeat eye exam 7 days
after treatment
Research pharmacist Review of phase 1 studies and
rationale for phase 2 studies§
Review of informed consent,
randomization and dosing§
Dosing of individual consented
subjects after their randomization
Nursing staff and cardiology
technical staff
Review of phase 1 studies and
the rationale for the phase 2
studies§
Obtaining timed venous blood
samples in relation to dosing§
Written notes each inpatient day
focused on results, possible AEs§
Clinical monitor Assessment of study design for
the phase 2 efficacy study†
Prepare operating procedures
and bilingual CRFs‖
Daily review of screening, consent,




Test equipment and supplies
using appropriate controls
Pilot studies (standardization)
based on healthy controls
in Mali‖
Hematology and chemistry panels,
malaria smears, G6PD testing
Administrative staff Review administrative/financial
issues for the phase 2 studies
Human studies training and
certification
Schedule patient transportation,
records of patient compensation
Scientific issues Basis of AQ-13 action against
CQ-resistant Plasmodium
falciparum¶
Safety, pharmacology of AQ-13
in healthy subjects¶
Importance of record keeping,
AEs, parasite genotype,
treatment failure¶
AEs = adverse events; CQ = chloroquine; CRFs = case report forms; PI = principal investigator.
*Human studies training and certification were required for study personnel in the United States and Mali.
†Training for the Mali PI, senior investigator, and internists was based on two 2-week visits to the United States and on workshops provided by the study PI and the director of the Tulane-
LSU Clinical Research Center in New Orleans.
‡Training on obtaining and interpreting 24-hour Holter recordings was provided to Mali cardiologists by the director of the Tulane Electrophysiology Unit in New Orleans.
§After approval by the Tulane and Mali Institutional Review Boards and Food and Drug Administration (FDA), the phase 2 study protocol was reviewed with the ophthalmology consultant,
research pharmacist, clinical monitor, and other clinical and laboratory staff in Mali by both the PI and the Mali PI. Screening of volunteers for normal vision was performed by an ophthalmol-
ogy consultant, treatment was provided by a research pharmacist, and timed blood specimens (in relation to dosing) were obtained by the nursing and technical staff.
‖Bilingual CRFs with numerical or yes/no responses were requested by FDA so study records (including CRFs) could be understood by reviewers who were fluent in English but not in
French. Please note that French is used for higher education (including medicine) and official government records in Mali. Standard operating procedures (SOPs) were also prepared in both
French and English (bilingual format), although that had not been requested by the FDA Review Panel for the investigational new drug application (IND) under which these studies were
performed (IND 055,670).
¶Scientific issues such as the preparation of SOPs and CRFs, the basis of aminoquinoline action against P. falciparum (including the activity of AQ-13 against CQ-resistant parasites), the
safety and pharmacokinetics of AQ-13 in healthy human subjects and the molecular basis of parasite genotyping were reviewed with investigators and the technical and nursing staff in Mali by
both the PI and Mali PI.
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practice and teaching in resource-limited regions. We propose
a regional rather than country-specific approach because the
underlying problems are regional (as exemplified by the
recent Ebola outbreak) and because it encourages the careful
evaluation of priorities and minimizes infrastructural (over-
head) costs. In conclusion, we urge international organizations
and funding agencies to support the development of clinical
research facilities and the training of host country investiga-
tors to facilitate rigorous and more expeditious evaluation of
candidate interventions and simultaneously improve the qual-
ity of medical and public health practice in resource-limited
regions. To maximize the probability of success, we recom-
mend these efforts focus on countries with schools of medicine
or public health already engaged in externally funded research
on disease control interventions and public health. These
essential priorities can no longer be ignored.
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